Close Menu

NEW YORK – Sermonix Pharmaceuticals announced on Tuesday that it had dosed the first patient in a Phase II clinical trial of its investigational drug, lasofoxifene, in combination with CDK 4/6 inhibitor abemaciclib (Eli Lilly's Verzenio).

The trial, called ELAINE 2, will evaluate lasofoxifene, a selective estrogen receptor modulator, in combination with abemaciclib in pre- and postmenopausal women with locally advanced, metastatic, estrogen receptor-positive, HER2-negative breast cancer and an ESR1 mutation in their tumors. The primary endpoint is progression-free survival.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Mar
11
Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
23
Sponsored by
Roche

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar
25
Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

Mar
30
Sponsored by
Menarini Silicon Biosystems

This webinar will provide an overview of the current state of circulating tumor cell (CTC) enumeration for clinical use in metastatic breast cancer.